Detection of metabolites discriminating subtypes of thyroid cancer: Molecular profiling of FFPE samples using the GC/MS approach

Molecular and Cellular Endocrinology

Volumn 417, Issue , 2015, Pages 149-157

  Wojakowska, Anna ^a   Chekan, Mykola ^a   Marczak, Łukasz ^b   Polanski, Krzysztof ^c   Lange, Dariusz ^a   Pietrowska, Monika ^a   Widlak, Piotr ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Clinical metabolomics; Follicular lesions; Formalin fixed paraffin embedded tissue specimen; Gas chromatography mass spectrometry; Thyroid cancer

Indexed keywords

2 MONOPALMITOYL GLYCEROL; 2 MONOSTEARIN; CARBOHYDRATE; CARBOXYLIC ACID; DECANOIC ACID DECYL ESTER; EICOSANOIC ACID PROPYL ESTER; ESTER DERIVATIVE; FORMALDEHYDE; GLYCEROL DERIVATIVE; GLYCEROL STEARATE; HEPTADECANOIC ACID GLYCERINE MONOESTER; HEXANOID PROPYL ESTER; INOSITOL PHOSPHATE; LACTIC ACID; LAURIC ACID PROPYL ESTER; LIPID; MYRISTIC PROPYL ESTER; NONADECANOIC ACID GLYCERINE MONOESTER; PARAFFIN; RIBOSE; RICINOLEIC ACID; SUCCINIC ACID; UNCLASSIFIED DRUG; POLYSACCHARIDE;

ANAPLASTIC THYROID CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CHEMOMETRIC ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID GLAND TISSUE; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION; ADENOCARCINOMA, FOLLICULAR; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION REGULATION; METABOLISM; METABOLOME; PROCEDURES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

ADENOCARCINOMA, FOLLICULAR; CARBOXYLIC ACIDS; DIAGNOSIS, DIFFERENTIAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPIDS; METABOLOME; POLYSACCHARIDES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84960253459     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.09.021     Document Type: Article

References (43)

1. Boss W.F., Davis A.J., Im Y.J., Galvao R.M., Perera I.Y. Phosphoinositide metabolism: towards an understanding of subcellular signaling. Subcell. Biochem. 2006, 39:181-205.
2. Brown L.M., Helmke S.M., Hunsucker S.W., Netea-Maier R.T., Chiang S.A., Heinz D.E., Shroyer K.R., Duncan M.W., Haugen B.R. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog. 2006, 45:613-626.
3. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
4. Deja S., Dawiskiba T., Balcerzak W., Orczyk-Pawiłowicz M., Głód M., Pawełka D., Młynarz P. Follicular adenomas exhibit a unique metabolic profile. 1H NMR studies of thyroid lesions. PLoS One 2013, 8:e84637.
5. DeLellis R.A., Lloyd R.V., Heitz P.U., Eng C. Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours 2004, IARC Press, Lyon.
6. Eszlinger M., Krohn K., Kukulska A., Jarzab B., Paschke R. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr. Rev. 2007, 28:322-338.
7. Eszlinger M., Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. Mol. Cell. Endocrinol. 2010, 322:29-37.
8. Faquin W.C. The thyroid gland: recurring problems in histologic and cytologic evaluation. Arch. Pathol. Lab. Med. 2008, 132:622-632.
9. Fernandis A.Z., Wenk M.R. Lipid-based biomarkers for cancer. J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci. 2009, 877:2830-2835.
10. Fujarewicz K., Jarzab M., Eszlinger M., Krohn K., Paschke R., Oczko-Wojciechowska M., Wiench M., Kukulska A., Jarzab B., Świerniak A. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr. Relat. Cancer 2007, 14:809-826.
11. Glaysher J. Lipid metabolism and cancer. Curr. Opin. Lipidol. 2013, 24:530-531.
12. Greco A., Borrello M.G., Miranda C., Degl'Innocenti D., Pierotti M.A. Molecular pathology of differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging 2009, 53:440-453.
13. Guo S., Qiu L., Wang Y., Qin X., Liu H., He M., Zhang Y., Li Z., Chen X. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal. Bioanal. Chem. 2014, 406:4357-4370.
14. Guo S., Wang Y., Zhou D., Li Z. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci. Rep. 2014, 4:5959.
15. Hedinger C., Williams E.D., Sobin L.H. Histological typing of thyroid tumors. International Histological Classification of Tumours 1998, vol. 11. Springer-Verlag, Berlin. second ed.
16. Hilvo M., Denkert C., Lehtinen L., Müller B., Brockmöller S., Seppänen-Laakso T., Budczies J., Bucher E., Yetukuri L., Castillo S., Berg E., Nygren H., Sysi-Aho M., Griffin J.L., Fiehn O., Loibl S., Richter-Ehrenstein C., Radke C., Hyötyläinen T., Kallioniemi O., Iljin K., Oresic M. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer. Res. 2011, 71:3236-3245.
17. Hood B.L., Stewart N.A., Conrads T.P. Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation. Clin. Lab. Med. 2009, 29:115-138.
18. Ide Y., Waki M., Hayasaka T., Nishio T., Morita Y., Tanaka H., Sasaki T., Koizumi K., Matsunuma R., Hosokawa Y., Ogura H., Shiiya N., Setou M. Human breast Cancer tissues contain abundant phosphatidylcholine (36:1) with high stearoyl-CoA desaturase-1 expression. PLoS One 2013, 8:e61204.
19. Ishikawa S., Tateya I., Hayasaka T., Masaki N., Takizawa Y., Ohno S., Kojima T., Kitani Y., Kitamura M., Hirano S., Setou M., Ito J. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS One 2012, 7:e48873.
20. Jarzab B., Wiench M., Fujarewicz K., Simek K., Jarzab M., Oczko-Wojciechowska M., Wloch J., Czarniecka A., Chmielik E., Lange D., Pawlaczek A., Szpak S., Gubala E., Swierniak A. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res. 2005, 65:1587-1597.
21. Kakudo K., Kameyama K., Miyauchi A., Nakamura H. Introducing the reporting system for thyroid fine-needle aspiration cytology according to the new guidelines of the Japan Thyroid Association. Endocr. J. 2014, 61:539-552.
22. Klopfleisch R., Weiss A.T., Gruber A.D. Excavation of a buried treasure-DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol. Histopathol. 2011, 26:797-810.
23. Lee G.K., Lee H.S., Park Y.S., Lee J.H., Lee S.C., Lee J.H., Lee S.J., Shanta S.R., Park H.M., Kim H.R., Kim I.H., Kim Y.H., Zo J.I., Kim K.P., Kim H.K. Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. Lung Cancer 2012, 76:197-203.
24. Lloyd R.V., Buehler D., Khanafshar E. Papillary thyroid carcinoma variants. Head. Neck Pathol. 2011, 5:51-56.
25. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
26. Miccoli P., Torregrossa L., Shintu L., Magalhaes A., Chandran J., Tintaru A., Ugolini C., Minuto M.N., Miccoli M., Basolo F., Caldarelli S. Metabolomics approach to thyroid nodules: a high-resolution magic-angle spinning nuclear magnetic resonance-based study. Surgery 2012, 152:1118-1124.
27. Nirmalan N.J., Harnden P., Selby P.J., Banks R.E. Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol. Biosyst. 2008, 4:712-720.
28. Oertel Y.C. Classification of thyroid malignancies. Thyroid Cancer: a Comprehensive Guide to Clinical Management 2004, 85-87. Humana Press, New Jersey. L. Wartofsky, D. Van Nostrand (Eds.).
29. Reimel B.A., Pan S., May D.H., Shaffer S.A., Goodlett D.R., McIntosh M.W., Yerian L.M., Bronner M.P., Chen R., Brentnall T.A. Proteomics on fixed tissue specimens - a review. Curr. Proteom. 2009, 6:63-69.
30. Rosai J., Carcangiu M.L., DeLellis R.A. Tumors of the Thyroid Gland. Atlas of Tumor Pathology 1992, Armed Forces Institute of Pathology, Washington, D.C.
31. Sakorafas G.H. Thyroid nodules; interpretation and importance of fine-needle aspiration (FNA) for the clinician - practical considerations. Surg. Oncol. 2010, 19:130-139.
32. Salabe G.B. Pathogenesis of thyroid nodules: histological classification?. Biomed. Pharmacother. 2001, 55:39-53.
33. Schlumberger M. Papillary and follicular thyroid carcinoma. Ann. Endocrinol. Paris. 2007, 68:120-128.
34. Silver C.E., Owen R.P., Rodrigo J.P., Rinaldo A., Devaney K.O., Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head. Neck 2011, 33:1052-1059.
35. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 2009, 15:431-440.
36. Stokowy T., Wojtaś B., Krajewska J., Stobiecka E., Dralle H., Musholt T., Hauptmann S., Lange D., Hegedüs L., Jarzab B., Krohn K., Paschke R., Eszlinger M. A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. Mol. Cell. Endocrinol. 2014, 399:43-49.
37. Stokowy T., Wojtaś B., Fujarewicz K., Jarzab B., Eszlinger M., Paschke R. miRNAs with the potential to distinguish follicular thyroid carcinomas from benign follicular thyroid tumors: results of a meta-analysis. Horm. Metab. Res. 2014, 46:171-180.
38. Torregrossa L., Shintu L., Nambiath Chandran J., Tintaru A., Ugolini C., Magalhaes A., Basolo F., Miccoli P., Caldarelli S. Toward the reliable diagnosis of indeterminate thyroid lesions: a HRMAS NMR-based metabolomics case of study. J. Proteome Res. 2012, 11:3317-3325.
39. Ustun B., Chhieng D., Prasad M.L., Holt E., Hammers L., Carling T., Udelsman R., Adeniran A.J. Follicular variant of papillary thyroid carcinoma: accuracy of FNA diagnosis and implications for patient management. Endocr. Pathol. 2014, 25:257-264.
40. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
41. Wojakowska A., Chekan M., Widlak P., Pietrowska M. Application of metabolomics in thyroid cancer research. Int. J. Endocrinol. 2015, 13. Article ID 258763.
42. Xing M., Haugen B.R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013, 381:1058-1069.
43. Yao Z., Yin P., Su D., Peng Z., Zhou L., Ma L., Guo W., Ma L., Xu G., Shi J., Jiao B. Serum metabolic profiling and features of papillary thyroid carcinoma and nodular goiter. Mol. Biosyst. 2011, 7:2608-2614.